CAS: 1182-87-2; (3S,5R,8R,9S,10R,13R,14S,17R)-3-[(2R,3S,4R,5S,6S)-3,5-Dihydroxy-4-Methoxy-6-Methyloxan-2-Yl]Oxy-14-Hydroxy-13-Methyl-17-(5-Oxo-2H-Furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-Tetradecahydrocyclopenta[a]Phenanthrene-10-Carbaldehyde

📜Alkaline Earth Salt Of/the/ Methylsulfuric Acid置于strophanthobiose-Substance体系中,化学反应生成夹次苷
参考文献:Cerberosid(thevetin B),Thevetin A和peruvosid的组成.糖苷和糖苷配基,第213部分
标题:Cerberosid(thevetin B),Thevetin A和peruvosid的组成.糖苷和糖苷配基,第213部分
摘要:描述了通过分配色谱法将粗制的维汀类药物分离为纯成分小ber苷(维汀b)和维汀a的过程.Cerberoside的构成我从转换与真菌淀粉酶或来自种子发酵一个制备thevebioside和neriifolin(v)如下cerbera Odollam.芥子油苷酶a(III)通过频闪霉素酶或上述来自cerbera Odollam的发酵制剂的作用被转化为普鲁佛苷(viii).后者代表血管生成素的α-L-Vevetoside,通过与1,3-丙二酚反应生成环状硫代缩酮vii,然后通过raney镍催化脱硫将其转化为neriifolin(v).
Doi:10.1002/hlca.19600430306

专利信息

专利号:US-2022160788-A1
优先权日:2019-03-22
标题 :Bifunctional vectors allowing bcl11a silencing and expression of an anti-sickling hbb and uses thereof for gene therapy of b-hemoglobinopathies
发明人：MICCIO ANNARITA; AMENDOLA MARIO; BRUSSON MÉGANE; CAVAZZANA MARINA; MAVILIO FULVIO
权利人:INST NAT SANTE RECH MED; UNIV DEVRY VAL DESSONNE; ASSIST PUBLIQUE HOPITAUX PARIS APHP; UNIV PARIS; FOND IMAGINE
摘要:The #β-hemoglobinopathies #β-thalassemia (BT) and sickle cell disease (SCD) are the most frequent genetic disorders worldwide. These diseases are caused by mutations causing reduced or abnormal synthesis of the β-globin chain of the adult hemoglobin (Hb) tetramer. Here, the inventors intend to improve HSC-based gene therapy for β-thalassemia and SCD by developing an innovative, highly infectious LV vector expressing a potent anti-sickling β-globin transgene and a second biological function either increasing fetal γ-globin expression (for β-thalassemia and SCD). More particularly, the inventors have designed a novel lentivirus (LV), which carry two different functions: βAS3 gene addition and gene silencing. This last strategy allows the re-expression of the fetal γ-globin genes (HBG1 and HBG2) and production of the endogenous fetal hemoglobin (HbF). Elevated levels of HbF and HbAS3 (Hb tetramer containing βAS3-globin) will benefit the β-hemoglobinopathy phenotype by increasing the total amount of β-like globin that will: (i) reduce the alpha precipitates and improve the alpha/non alpha ratio in β-thalassemia, and (ii) reduce the sickling in SCD. This combined strategy will improve the β-hemoglobinopathy phenotype at a lower vector copy number (VCN) per cell compared to a LV expressing the βAS3 alone.

专利号:US-9907753-B2
优先权日:2010-03-19
标 题 :Lipid vesicle compositions and methods of use
发明人：IRVINE DARRELL J; MOON JAEHYUN
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents.

专利号:CN-101678118-A
优先权日:2006-10-05
标 题:Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

专利号:CN-104800862-A
优先权日:2006-10-05
标题 :Efficient synthesis, compositions and uses of chelators for nuclear imaging and radiotherapy